spacer
home > ebr > spring 2007 > rheum for improvement
PUBLICATIONS
European Biopharmaceutical Review

Rheum for Improvement

Antibody and circulating receptor therapeutics that target Tumour Necrosis Factor alpha (TNF-α) are routinely used to treat rheumatoid arthritis, but these biological therapies can be difficult and expensive to manufacture. Dr Hans Christian Thørgersen of Borean Pharma presents alternative approaches

Rheumatoid arthritis (RA) is one of the most common forms of arthritis, with a prevalence worldwide of about one per cent. It is a chronic, inflammatory, multisystem, autoimmune disorder that affects the joints in a polyarticular manner. RA can be distinguished from other forms of arthritis in that it is characterised by inflammation and soft-tissue swelling of many joints at the same time (polyarthritis). As the disease progresses, it gradually affects all joints in the body and the inflammatory activity leads to erosion and destruction of the joint surface, which impairs their range of movement and leads to deformity. Some relief from pain can be achieved through use of the affected joints, meaning that stiffness and joint pain is at its most acute first thing in the morning.

Examination of the synovium in RA patients indicated that cytokines are important in mediating the inflammatory process. In particular, tumour necrosis factor alpha (TNF-α) has emerged as a proinflammatory cytokine with a key role to play (1). TNF-α inhibition is therefore a logical strategy in the treatment of RA.

ANTI-TNF ANTIBODY THERAPEUTICS

This has led to the development of monoclonal antibodies such as Remicade (Infliximab, Centocor Inc) (2) and Humira (Adalibumab, Abbott Laboratories) (3) and the p75 TNF-α receptor – immunoglobulin Fc fusion protein, Enbrel (Etanercept, Amgen/Wyeth) (4) as diseasemodifying treatments for RA. Blockade of TNF-α using each of these treatments reduces the signs and symptoms of inflammation and also appears to retard the destruction of joints through disease progression.

However, treatment with these anti-TNF-α therapies is expensive – in the region of about ˆ7,000-10,000 a year per patient – which limits their availability in most countries to only certain patients. Part of the reason for this high cost is the fact that these antibody therapeutics are needed in substantial quantities to achieve their therapeutic effects. Administering such large amounts of antibody to a patient carries its own risks. An additional factor is the cost of manufacturing, as each of these RA treatments is produced in costly rate-limiting mammalian cell-culture. This in turn means that production cannot be easily accommodated to large increases in demand.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hans Christian Thøgersen, MSc, PhD, is Chief Scientific Officer (CSO) and co-founder of Borean Pharma, and Associate Professor at the University of Aarhus. He has 25 years’ research experience in molecular biology. For a decade, he led the Danish Biotechnology Programme for Protein Engineering as Project Coordinator and has been awarded several international research grants, including one from the international Human Frontiers of Science programme. Hans was among the first to establish protein-engineering research at the MRC Laboratory of Molecular Biology and the first to introduce this research area to Denmark, co-funding the Aarhus University Laboratory of Gene Expression. He holds a Masters and a PhD in Chemistry Physics and Molecular Biology respectively. Further to his academic achievements, he co-founded Denzyme ApS and Borean Pharma.
spacer
Hans Christian Thøgersen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kallik’s Release 6 sets new benchmarks for speed, accuracy and efficiency

Tamworth, UK – 15 June 2019 – Global provider of labelling and artwork management solutions, Kallik, is launching an update to its AMS360 solution – its Release 6, transforming the experience of the business user, whilst defining new benchmarks for speed, accuracy, and efficiency of global labelling and artwork processes.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement